Efruxifermin (AKR-001) is an investigational drug developed by Akero Therapeutics, acting as a fibroblast growth factor 21 (FGF21) analog developed to treat metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), and type 2 diabetes. [1] [2] [3]Efruxifermin is designed to mimic the biological activity of FGF21, which is a …

2021年7月8日 · Efruxifermin is a fusion protein of human IgG 1 Fc domain linked to a modified human FGF21 (Fc-FGF21) with balanced in vitro agonist potency at FGFR1c, FGFR2c and FGFR3c 14....

Efruxifermin significantly reduced liver fibrosis in MASH patients with F2–F3 fibrosis, with sustained improvement in liver injury and resolution of steatohepatitis over 96 weeks (HARMONY phase 2b study)

Our multi-modal investigational drug, efruxifermin (EFX), is designed to treat MASH holistically. EFX has been engineered to mimic the biological activity of fibroblast growth factor 21 (FGF21), which regulates multiple metabolic pathways and cellular processes.

In this challenging well-compensated cirrhotic population, a clinically meaningful but not yet significant clinical benefit was seen in as early as 36 weeks. The totality of the data to include markers of liver injury and fibrosis suggest overall improvement of liver health at …

2023年10月3日 · Efruxifermin is a bivalent Fc-FGF21 analogue that replicates FGF21 agonism of fibroblast growth factor receptor 1c, 2c, or 3c. The aim of this phase 2b study was to assess its efficacy and safety in patients with non-alcoholic steatohepatitis (NASH) and moderate (F2) or severe (F3) fibrosis.

2024年3月4日 · Efruxifermin improves liver histology and markers of liver injury and fibrosis in patients with MASH. In this 12-week phase 2b study, efruxifermin, added to a GLP-1RA in patients with MASH and T2D, had an acceptable safety profile with mostly mild to moderate gastrointestinal adverse events.

Areas covered: Efruxifermin (EFX, also AKR-001 or AMG876) is an engineered Fc-FGF21 fusion protein with an optimized pharmacokinetic and pharmacodynamic profile, which is currently tested in several phase 2 clinical trials for the treatment of …

Efruxifermin is an Fc‐FGF21 fusion protein with prolonged half‐life and enhanced receptor affinity compared with native human FGF21. Efruxifermin is in clinical trials for the treatment of non‐alcoholic steatohepatitis. Experimental Approach. Efruxifermin was administered weekly to male and female Sprague Dawley rats for 4 or 26 weeks.

Preclinical and clinical data suggest that fibroblast growth factor 21 (FGF21) is anti-fibrotic, improves metabolic status and has potential to treat non-alcoholic steatohepatitis (NASH). We assessed the safety and efficacy of efruxifermin, a long-acting Fc …